Epidarex Capital

Epidarex Capital is a transatlantic venture capital firm specializing in early-stage investments across life science and health technology. The firm strategically targets emerging, under-ventured research hubs in the UK and US, providing equity capital to start-ups and university spin-outs. It leverages an extensive network to identify and support transformative scientific advancements, bridging research with commercialization.

Established in 2012, Epidarex Capital was co-founded by Kyparissia Sirinakis and A. Sinclair Dunlop. Their founding insight addressed a critical demand for specialized financial backing for nascent life science companies, particularly those from academic institutions. They aimed to foster innovation by supporting high-potential ventures in regions traditionally overlooked by venture capital.

The firm's portfolio comprises early-stage life science and health technology enterprises, often university spin-offs. Epidarex Capital’s vision centers on nurturing these ventures from inception, collaborating closely with management to translate foundational research into viable businesses. It seeks to drive the successful commercialization of innovative healthcare solutions.